Pharsight

Drugs that contain Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate

1. Atripla patents expiration

ATRIPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5519021 GILEAD SCIENCES Benzoxazinones as inhibitors of HIV reverse transcriptase
May, 2013

(10 years ago)

US5814639 GILEAD SCIENCES Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5914331 GILEAD SCIENCES Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

US5922695 GILEAD SCIENCES Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US5935946 GILEAD SCIENCES Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

US5977089 GILEAD SCIENCES Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US6939964 GILEAD SCIENCES Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
Jan, 2018

(6 years ago)

US6639071 GILEAD SCIENCES Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
Feb, 2018

(6 years ago)

US6703396 GILEAD SCIENCES Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5811423 GILEAD SCIENCES Benzoxazinones as inhibitors of HIV reverse transcriptase
Aug, 2012

(11 years ago)

US5519021

(Pediatric)

GILEAD SCIENCES Benzoxazinones as inhibitors of HIV reverse transcriptase
Nov, 2013

(10 years ago)

US5663169 GILEAD SCIENCES Benzoxazinones as inhibitors of HIV reverse transcriptase
Sep, 2014

(9 years ago)

US5663169

(Pediatric)

GILEAD SCIENCES Benzoxazinones as inhibitors of HIV reverse transcriptase
Mar, 2015

(9 years ago)

US5814639

(Pediatric)

GILEAD SCIENCES Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Mar, 2016

(8 years ago)

US6043230 GILEAD SCIENCES Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5914331

(Pediatric)

GILEAD SCIENCES Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jan, 2018

(6 years ago)

US5935946

(Pediatric)

GILEAD SCIENCES Nucleotide analog composition and synthesis method
Jan, 2018

(6 years ago)

US5977089

(Pediatric)

GILEAD SCIENCES Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US6043230

(Pediatric)

GILEAD SCIENCES Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US5922695

(Pediatric)

GILEAD SCIENCES Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jan, 2018

(6 years ago)

US6939964

(Pediatric)

GILEAD SCIENCES Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
Jul, 2018

(5 years ago)

US6639071

(Pediatric)

GILEAD SCIENCES Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
Aug, 2018

(5 years ago)

US6642245 GILEAD SCIENCES Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US6642245

(Pediatric)

GILEAD SCIENCES Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
May, 2021

(2 years ago)

US6703396

(Pediatric)

GILEAD SCIENCES Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Sep, 2021

(2 years ago)

US8592397 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US9744181 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US8716264 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US9457036 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US8716264

(Pediatric)

GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jul, 2024

(2 months from now)

US9545414 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(2 years from now)

US9018192 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(2 years from now)

US8598185 GILEAD SCIENCES Unitary pharmaceutical dosage form
Apr, 2029

(5 years from now)

Market Authorisation Date: 12 July, 2006

Treatment: Treatment of hiv-1 infection in adults; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage

ATRIPLA family patents

Family Patents